Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic ...
Pivotal Phase 2 with lasme-cel in r/r B-ALL (BALLI-01 trial) ongoing Phase 1: 83% ORR at RP2D and 100% ORR in the target Phase 2 population In target Phase 2 population: 100% of patients became eligible to transplant Pivotal Phase 2 first interim analysis expected in Q4 2026 BLA submission anticipated in 2028 Phase 1 with eti-cel in r/r NHL (NATHALI-01 trial) ongoing Best-in-class dual allogeneic CAR-T cell product targeting CD20 & CD22 At current dose level, 88% ORR; 63% CR rate after 2+ prior lines of therapy 93% of subjects had prior CD19 CAR-T Low-dose IL-2 cohort to be included in; Full Phase 1 dataset expected in Q4 2026 Partnerships Servier (through Allogene): Pivotal randomized Phase 2 ALPHA3 trial with cema-cel in 1L consolidation in LBCL: interim futility analysis evaluating MRD clearance and early safety results planned for April 2026 AstraZeneca: Activities progressing under the Joint Research and Collaboration Agreement Cash, cash equivalents and fixed-term deposits of $211 million as of December 31, 2025 1 provides runway into H2 2027 provides runway into H2 2027 Conference call scheduled on March 20, 2026 at 8:00 am ET / 1:00 pm CET NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today provided financial results for the fourth quarter and full year 2025, ending December 31, 2025 and provided a business update. “Lasme-cel demonstrated a potentially transformative efficacy profile in one of oncology’s most challenging settings, achieving 100% overall response rate in the target Phase 2 population. Critically, lasme-cel converted all patients in the target population into transplant-eligible candidates. The pivotal Phase 2 is now enrolling, and with a BLA submission anticipated in 2028, lasme-cel is on a clear regulatory path to potentially becoming the first off-...
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : 100 % des patients sont devenus éligibles à une greffe. Analyse intermédiaire de phase 2 pivot attendue en Q4 2026. Dépôt de demande d'autorisation de mise sur le marché (BLA) prévue ...
Phase 2 pivot évaluant lasmé-cel dans la LAL-B en rechute ou réfractaire (étude BALLI-01) en cours Phase 1 : 83 % d’ORR à la dose RP2D et 100 % d’ORR dans la population cible de phase 2. Population cible de phase 2 : 100 % des patients sont devenus éligibles à une greffe. Analyse intermédiaire de phase 2 pivot attendue en Q4 2026. Dépôt de demande d'autorisation de mise sur le marché (BLA) prévue en 2028. Phase 1 évaluant éti-cel dans le LNH en rechute ou réfractaire (étude NATHALI-01) en cours Éti-cel : “best-in-class" CAR-T allogénique à double cibles CD20 et CD22. Au niveau de dose actuel : 88 % d’ORR et 63 % de taux de RC chez des patients ayant reçu au moins 2 lignes de traitement antérieures. 93 % des patients avaient déjà reçu un traitement par CAR-T anti-CD19. Intégration d'une cohorte avec IL-2 à faible dose en cours. L’ensemble des données de phase 1 attendu en Q4 2026. Partenariats Servier (à travers Allogene) : essai pivot de phase 2 randomisé (ALPHA3) évaluant cema-cel en traitement de consolidation de première ligne dans le lymphome diffus à grandes cellules B (LBCL). Analyse intermédiaire de futilité, portant sur la clairance de la MRD et premiers résultats de sécurité prévue en avril 2026. AstraZeneca : les activités progressent conformément à l’accord de recherche et de collaboration. Trésorerie, équivalents de trésorerie et dépôts à terme de 211 millions de dollars au 31 décembre 2025 1 ; projection de trésorerie jusqu’au second semestre 2027. ; projection de trésorerie jusqu’au second semestre 2027. Conférence téléphonique le 20 mars 2026 à 8h00, heure de New York / 13h00, heure de Paris. NEW YORK, 20 mars 2026 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS ; Nasdaq : CLLS), société de biotechnologie de stade clinique, qui utilise sa plateforme pionnière d'édition de génome pour développer des thérapies innovantes pour le traitement de maladies graves, présente aujourd’hui ses résultats pour le quatrième trimestre 2025 et l’exercice 202...
In this article IGV APO Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 3:27 03:27 Volatile times create the best investing opportunities, says Apollo's David Sambur Money Movers Apollo Global Management 's David Sambur told CNBC on Thursday that the selloff in software stocks from fears of artificial intelligence disruption is far from over. "I unfortunately think it's very early,...
In this article IGV APO Follow your favorite stocks CREATE FREE ACCOUNT watch now VIDEO 3:27 03:27 Volatile times create the best investing opportunities, says Apollo's David Sambur Money Movers Apollo Global Management 's David Sambur told CNBC on Thursday that the selloff in software stocks from fears of artificial intelligence disruption is far from over. "I unfortunately think it's very early," Sambur, who is co-head of private equity, told CNBC's "Money Movers." Some Wall Street analysts have been comforted by the recent rebound in the IGV Software ETF , which has climbed about 3% in March following a bruising start to the year. The ETF is still down 20% this year. Sambur said software names are under scrutiny and facing critical questions about the revenue model, the gross margin profile, the competitive environment with Anthropic and OpenAI and the valuations. "I know the markets are moving up and they've rebounded a little bit, but I don't see any of those four things changing because of the real question mark about what the impact [is] of AI lowering the cost to compete, and therefore increasing the level of competition," he said. Sambur, who joined Apollo in 2004, said the displacement from AI will be historic and "is faster than I've ever seen at any point in my career." Read more CNBC tech news Micron revenue almost triples, tops estimates as demand for memory soars Uber to invest up to $1.25 billion in EV maker Rivian in deal to launch 50,000 robotaxis Meta is shutting down VR social platform Horizon Worlds in further pivot away from the metaverse Meta’s Manus launches desktop app to bring its AI agent onto personal devices amid OpenClaw craze Part of the issue, Sambur said, is that the industry is unable to figure out how the software story will evolve in the next one to five years because the technology itself is constantly changing. "No one knows," he said. "People are now recalibrating the valuations and baking in more margin of safety for very larg...
Minnesota Audit: State Agency 'Accidentally' Blocked Kickback Investigation Into Autism Services Authored by Janice Hisle via The Epoch Times (emphasis ours), A state agency erred when it blocked autism-services kickbacks from being investigated —a decision based on the agency’s flawed, decades-old definition of “fraud,” according to a Minnesota audit released March 17. A view outside the Minnesot...
Minnesota Audit: State Agency 'Accidentally' Blocked Kickback Investigation Into Autism Services Authored by Janice Hisle via The Epoch Times (emphasis ours), A state agency erred when it blocked autism-services kickbacks from being investigated —a decision based on the agency’s flawed, decades-old definition of “fraud,” according to a Minnesota audit released March 17. A view outside the Minnesota State Capitol building in Minneapolis, Minn., on June 20, 2020. Stephen Maturen/Getty Images That was the key finding of the state’s Office of Legislative Auditor, a state watchdog that conducted a two-year special review. The autism-services program that auditors examined is among many health and welfare benefits that Minnesota’s Department of Human Services runs or oversees. For months, Minnesota has been a focal point for government-program fraud that could total billions of dollars, with dozens of people, mostly Somalis, having been charged and convicted since 2022. Additional schemes emerged late last year and remain under investigation, with more charges expected, prosecutors have said. Concerns about fraud have recently expanded nationwide. On March 16, President Donald Trump signed an executive order creating an anti-fraud task force. Saying that other states such as California and New York may have fraud problems that are worse than Minnesota’s, the president directed Vice President JD Vance and Federal Trade Commission Chairman Andrew Ferguson to root out fraud in federally funded social services and welfare programs. During the Minnesota audit, investigators told auditors that they believed they lacked “authority to investigate allegations of kickbacks” in the autism program without additional claims of “fraud, theft, abuse, or error.” The department’s fraud definition, set in 1995, failed to specifically include “kickbacks.” Those are payments or “anything of value” to induce referrals to providers of federally funded health care—a practice that is illegal und...
Explore the exciting world of L3Harris Technologies (NYSE: LHX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 19, 2026. Should you buy stock in L3Harris Technologies right ...
Explore the exciting world of L3Harris Technologies (NYSE: LHX) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market trends and potential investment opportunities! *Stock prices used were the prices of Feb. 4, 2026. The video was published on March 19, 2026. Should you buy stock in L3Harris Technologies right now? Before you buy stock in L3Harris Technologies, consider this: Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue » The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and L3Harris Technologies wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $510,710!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,105,949!* Now, it’s worth noting Stock Advisor’s total average return is 927% — a market-crushing outperformance compared to 186% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors. See the 10 stocks » *Stock Advisor returns as of March 19, 2026. Anand Chokkavelu has no position in any of the stocks mentioned. Lou Whiteman has positions in L3Harris Technologies. Travis Hoium has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends L3Harris Technologies. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Steven Foster Chief Financial Officer — Kevin Williamson Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Revenue -- $1.5 million in the quarter, up 92% with new physician adoption driving procedure growth. -- $1.5 million in the quarter, up 92% with new phy...
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Steven Foster Chief Financial Officer — Kevin Williamson Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Revenue -- $1.5 million in the quarter, up 92% with new physician adoption driving procedure growth. -- $1.5 million in the quarter, up 92% with new physician adoption driving procedure growth. Full Year Revenue -- $3.9 million, representing 20% growth. -- $3.9 million, representing 20% growth. Gross Profit -- $1 million for the quarter, a 188% increase, with gross margin rising to 69% from 46%, due to improved operational efficiencies and higher revenue absorption of fixed costs. -- $1 million for the quarter, a 188% increase, with gross margin rising to 69% from 46%, due to improved operational efficiencies and higher revenue absorption of fixed costs. Operating Expenses -- $3.9 million, up from $3.5 million a year prior, attributable to increased sales and marketing variable costs tied to revenue growth. -- $3.9 million, up from $3.5 million a year prior, attributable to increased sales and marketing variable costs tied to revenue growth. Full Year Operating Expenses -- $15.2 million, down from $15.5 million, primarily due to reduced general and administrative expenses offset by increased commercial investment. -- $15.2 million, down from $15.5 million, primarily due to reduced general and administrative expenses offset by increased commercial investment. Net Loss -- $2.8 million, or $0.29 per share, a reduction from $3.1 million, or $0.98 per share, in the prior-year quarter driven by improved operating leverage. -- $2.8 million, or $0.29 per share, a reduction from $3.1 million, or $0.98 per share, in the prior-year quarter driven by improved operating leverage. Cash Position -- $3.8 million in cash and cash equivalents at period end, with zero outstanding debt. -- $3.8 million in cash and cash equivalents at period e...
Image source: The Motley Fool. Thursday, Mar. 19, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Dr. Sergio Traversa Chief Medical Officer, Oncology — Dr. Raj S. Pruthi Chief Financial Officer — Maged S. Shenouda Need a quote from a Motley Fool analyst? Email [email protected] Takeaways NDV01 Phase II data -- The 12-month complete response rate reached 76% in high-risk non-muscle...
Image source: The Motley Fool. Thursday, Mar. 19, 2026 at 4:30 p.m. ET Call participants Chief Executive Officer — Dr. Sergio Traversa Chief Medical Officer, Oncology — Dr. Raj S. Pruthi Chief Financial Officer — Maged S. Shenouda Need a quote from a Motley Fool analyst? Email [email protected] Takeaways NDV01 Phase II data -- The 12-month complete response rate reached 76% in high-risk non-muscle invasive bladder cancer (NMIBC) patients, with 80% in the BCG-unresponsive subgroup. -- The 12-month complete response rate reached 76% in high-risk non-muscle invasive bladder cancer (NMIBC) patients, with 80% in the BCG-unresponsive subgroup. Safety outcomes -- No progression to muscle-invasive disease, no radical cystectomy, and no grade 3 or higher treatment-related adverse events were observed during the 12-month period; most adverse events were grade 1. -- No progression to muscle-invasive disease, no radical cystectomy, and no grade 3 or higher treatment-related adverse events were observed during the 12-month period; most adverse events were grade 1. Planned Phase III design -- The RESCUE program, developed in FDA alignment, includes two registrational pathways: one for adjuvant therapy in intermediate-risk bladder cancer (about 75,000 U.S. patients annually), and another as second-line therapy for BCG-unresponsive patients (about 5,000 U.S. patients). -- The RESCUE program, developed in FDA alignment, includes two registrational pathways: one for adjuvant therapy in intermediate-risk bladder cancer (about 75,000 U.S. patients annually), and another as second-line therapy for BCG-unresponsive patients (about 5,000 U.S. patients). Phase III initiation timeline -- IND clearance and launch of the RESCUE program are targeted for mid-year, with three-month response data expected from the BCG-unresponsive study by year-end. -- IND clearance and launch of the RESCUE program are targeted for mid-year, with three-month response data expected from the BCG-unresponsive study ...
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder and Chief Executive Officer — Darren Lampert Chief Financial Officer — Greg Sanders Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Net Sales -- $37.8 million in the quarter, up $0.4 million despite eight fewer retail locations versus the prior year period. -- $37.8 milli...
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Co-Founder and Chief Executive Officer — Darren Lampert Chief Financial Officer — Greg Sanders Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Net Sales -- $37.8 million in the quarter, up $0.4 million despite eight fewer retail locations versus the prior year period. -- $37.8 million in the quarter, up $0.4 million despite eight fewer retail locations versus the prior year period. Full Year Net Sales -- $161.7 million, reflecting an expected decrease driven by store closures. -- $161.7 million, reflecting an expected decrease driven by store closures. Proprietary Brand Penetration -- 35.8% of cultivation and gardening revenue in the quarter, up from 30.4% in the prior year. -- 35.8% of cultivation and gardening revenue in the quarter, up from 30.4% in the prior year. Full Year Proprietary Brand Sales -- 32.8% of cultivation and gardening sales, up from 24.2%, equating to $44 million, an 11.3% increase. -- 32.8% of cultivation and gardening sales, up from 24.2%, equating to $44 million, an 11.3% increase. Gross Profit -- $9.1 million in the quarter, a $3 million increase from the prior-year period, with fourth-quarter gross margin at 24.1%, up from 16.4%. -- $9.1 million in the quarter, a $3 million increase from the prior-year period, with fourth-quarter gross margin at 24.1%, up from 16.4%. Full Year Gross Profit Margin -- 26.8%, representing a 370 basis point improvement. -- 26.8%, representing a 370 basis point improvement. Total Operating Expenses -- Declined by $13.3 million, or 45.3%, in the quarter compared to the prior year period, totaling $16.7 million. -- Declined by $13.3 million, or 45.3%, in the quarter compared to the prior year period, totaling $16.7 million. Full Year Operating Expense Reduction -- $27 million removed from operating expenses, a 28% decline. -- $27 million removed from operating expenses, a 28% decline. Non-GAAP Adjus...
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Daniel Goldberger Chairman — Dr. Thomas Errico Chief Financial Officer and Interim President — Joshua Lev Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Leadership Transition -- Daniel Goldberger announced retirement as CEO effective April 1, 2026; Joshua ...
Image source: The Motley Fool. Thursday, March 19, 2026 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Daniel Goldberger Chairman — Dr. Thomas Errico Chief Financial Officer and Interim President — Joshua Lev Need a quote from a Motley Fool analyst? Email [email protected] TAKEAWAYS Leadership Transition -- Daniel Goldberger announced retirement as CEO effective April 1, 2026; Joshua Lev appointed Interim President in addition to CFO responsibilities, and Michael Fox will join as Chief Operating Officer in April. -- Daniel Goldberger announced retirement as CEO effective April 1, 2026; Joshua Lev appointed Interim President in addition to CFO responsibilities, and Michael Fox will join as Chief Operating Officer in April. Total Revenue -- Full-year revenue reached $32 million, a 27% increase; fourth-quarter revenue was $9.2 million, up 31% year over year. -- Full-year revenue reached $32 million, a 27% increase; fourth-quarter revenue was $9.2 million, up 31% year over year. VA Channel Revenue -- Prescription sales through the U.S. Veterans Affairs (VA) channel rose to $26 million, a 23% increase, primarily from gammaCore and Quell products. -- Prescription sales through the U.S. Veterans Affairs (VA) channel rose to $26 million, a 23% increase, primarily from gammaCore and Quell products. VA Facility Penetration -- As of year-end, electroCore ECOR 5.00% ) -- As of year-end, gammaCore VA Patient Reach -- Approximately 13,400 VA patients have used gammaCore, representing about 2% of the estimated addressable VA headache market. -- Approximately 13,400 VA patients have used gammaCore, representing about 2% of the estimated addressable VA headache market. Quell Asset Contribution -- Acquisition in May generated $1.5 million in revenue since joining the portfolio. -- Acquisition in May generated $1.5 million in revenue since joining the portfolio. General Wellness Revenue -- Wellness product sales, led by Truvaga, totaled $5.5 million for the year (up 97%),...